In this issue:
RAPDIO: neoadjuvant strategies in high-risk rectal cancer
FOxTROT: NACT feasible for resectable colon cancer
Codon-specific KRAS mutations predict benefit from chemo in mCRC
Targeted triplet combo active in BRAF V600E mutated mCRC
Perioperative chemotherapy in CRC with peritoneal metastases
Liver metastases reduce efficacy of pembrolizumab in dMMR mCRC
Minimal response to bintrafusp alfa in molecularly unselected CRC
Neuropathy linked to longer oxaliplatin duration, obesity and diabetes
Adjuvant oxaliplatin duration can be halved in stage 3 colon cancer
Optimising neoadjuvant therapy for elderly patients with rectal cancer
Please login below to download this issue (PDF)